what's glp 1 GLP-1 vs. GLP-1 + GIP: the Difference for your Metabolism? GLP-ONE + Receptor Activator
Description
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
The phase 2 dose-ranging trial (NCT02970942) included 320 individuals with histologically proven MASH and hepatic fibrosis F1-F3, randomizing them 3:3:3:1:1:1 to daily subcutaneous administration of semaglutide 0.1, 0.2, or 0.4 mg, or placebo for 72 weeks [18]
Recent reports suggest that as of 2022, 12% of adults in the United States have taken a GLP-1 agonist for weight loss at some point
[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Shetty R., Basheer F.T., Poojari P.G., Thunga G., Chandran V.P., Acharya L.D
E.JansonJ.Bonner-WeirS.RitzelR.RizzaR
Reduced inflammation may be one of the reasons, including weight loss and better blood sugar control, why
